AKT1 and gastric cancer: These results imply that the blockade of NRP-1 using specific monoclonal antibodies may represent a new and effective therapeutic strategy for gastric cancer, primarily through the inhibition of tumor cell migration and invasion via modulation of the PI3K/Akt signaling pathway [28].